AMAG Pharmaceuticals, Inc. (AMAG) Upgraded at Zacks Investment Research

Evrard Martin
Août 12, 2017

The fund owned 123,814 shares of the specialty pharmaceutical company's stock after selling 8,796 shares during the period. The value of the investment in AMAG Pharmaceuticals, Inc. went from $2,280,000 to $1,110,000 a change of $1,170,000 since the last quarter. With 1.08M avg volume, 8 days are for Amag Pharmaceuticals Incorporated (NASDAQ:AMAG)'s short sellers to cover AMAG's short positions. Renaissance Technologies LLC increased its stake in shares of AMAG Pharmaceuticals by 1.7% in the second quarter. Zacks Investment Research raised shares of AMAG Pharmaceuticals from a "hold" rating to a "buy" rating and set a $22.00 price objective on the stock in a research note on Tuesday, July 11th. Norges Bank purchased a new stake in shares of AMAG Pharmaceuticals during the fourth quarter valued at $19,914,000. Parametric Portfolio Associates LLC increased its stake in shares of AMAG Pharmaceuticals by 17.2% in the second quarter. California Public Employees Retirement System now owns 82,800 shares of the specialty pharmaceutical company's stock worth $1,524,000 after buying an additional 1,800 shares in the last quarter. Jefferies Group LLC set a $40.00 price objective on shares of AMAG Pharmaceuticals and gave the company a "buy" rating in a research report on Thursday, April 20th. Mason Street Advisors LLC now owns 8,030 shares of the specialty pharmaceutical company's stock valued at $181,000 after buying an additional 554 shares during the last quarter. Finally, Municipal Employees Retirement System of MI increased its stake in shares of AMAG Pharmaceuticals by 6.6% in the second quarter. Tiaa Cref Investment Management LLC now controls 173,023 shares valued at $3,184,000.

Shares of AMAG Pharmaceuticals (AMAG) opened at 16.75 on Tuesday. (NASDAQ:AMAG) shares saw light trading volume with 986K shares changing hands by the end of trading on Friday. The company's stock had a trading volume of 1,028,289 shares. The firm has "Hold" rating by BMO Capital Markets given on Wednesday, June 21. Company shares last traded at $16.75 which is significantly lower than the 50 day moving average of $19.12 and which is well below the 200 day moving average of $20.89.

AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.58) by $0.18. AMAG Pharmaceuticals had a negative net margin of 7.58% and a negative return on equity of 4.81%. The firm had revenue of $158.39 million during the quarter, compared to the consensus estimate of $158.83 million. During the same period previous year, the business posted $1.45 EPS. AMAG Pharmaceuticals's revenue for the quarter was up 24.3% compared to the same quarter a year ago. Equities research analysts expect that AMAG Pharmaceuticals, Inc. will post ($1.37) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: "AMAG Pharmaceuticals, Inc". If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of United States and worldwide copyright and trademark law. The legal version of this piece of content can be accessed at https://stocknewstimes.com/2017/08/11/amag-pharmaceuticals-inc-amag-stock-rating-reaffirmed-by-cantor-fitzgerald-updated-updated.html.

A number of analysts have recently commented on AMAG shares. Barclays PLC reiterated a "hold" rating and issued a $25.00 price objective on shares of AMAG Pharmaceuticals in a research report on Friday, May 5th. TheStreet lowered AMAG Pharmaceuticals from a c rating to a d+ rating in a research report on Friday, May 5th. ValuEngine upgraded shares of AMAG Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Tuesday, July 25th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have issued a buy rating to the company's stock. AMAG Pharmaceuticals has an average rating of "Hold" and an average price target of $28.09.

In other news, SVP Julie Krop sold 4,938 shares of AMAG Pharmaceuticals stock in a transaction on Thursday, July 13th. The stock was sold at an average price of $20.00, for a total value of $98,760.00. The SVP Clinical & Regulatory, CMO now owns $566,720 of the stock per the Form 4 SEC filing. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The stock decreased 3.28% or $0.09 on August 10, reaching $2.65. Amag Pharmaceuticals Inc now has $582.26 million valuation. The Company's segment is the manufacture, development and commercialization of services and products for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. The Company has a portfolio of products and services with a focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol) for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

D'autres rapports CampDesrEcrues

Discuter de cet article

SUIVRE NOTRE JOURNAL